Have you had trastuzumab deruxtecan (Enhertu)?

[Holly_BCN]

Hi all, 

As mentioned the treatment referenced earlier in this thread, trastuzumab deruxtecan (also known as Enhertu), is currently being assessed by NICE for use on the NHS for HER2 secondary breast cancer after 2 or more prior lines of treatments.

As well as hearing from people with experience of the drug (trastuzumab deruxtecan), we are also interested to hear from the following group of people to help with our response to NICE about this new treatment option -

• People who are currently on their third or fourth line of treatment for HER2 positive secondary breast cancer who have already received Kadcyla. We would like to hear people's experience of their current treatment (which could be eribulin or another chemotherapy). 

If you are able to help, please complete this short form https://breastcancernow.org/about-us/tell-us-your-story by 12th August and mention that you are responding to a post about trastuzumab deruxtecan 

Thanks and best wishes,

Holly (Policy and Campaigns team at Breast Cancer Now)

[Holly_BCN]

Hi Angel Eyes,

Thanks for your questions.

This treatment is being assessed for use after 2 or more anti-HER2 treatments. For example,  previous treatments might include trastuzumab (Herceptin) with pertuzumab (Perjeta) and trastuzumab emtansine (Kadcyla) too. 

The group of patients that could be eligible for this treatment will be considered as part of the assessment of this treatment for use on the NHS. 

Thanks and best wishes,

Holly

[Guest user]

Hello Holly,

Sorry if I appear stupid but would I be eligible for this drug? I am HER2 positive and currently have Trastuzumab and Pertuzumab as part of my current secondary treatment. 

Could I only go onto this drug if both Herceptin and Perjeta fail? Is that correct? Is it considered a first or second line treatment? 

Thank you

Angel Eyes

[Holly_BCN]

Hello everyone,

My name’s Holly and I work in the Policy, Evidence and Influencing Team at Breast Cancer Now.

The drug trastuzumab deruxtecan (also known as Enhertu) is being assessed for use on the NHS by the National Institute for Health and Care Excellence (NICE) for the treatment of HER2 positive secondary breast cancer, after 2 or more anti-HER2 treatments.

We're currently gathering evidence and insights to help inform our response on what access to this drug would mean for this group of patients. As part of this we would like to speak to anybody who has received the drug treatment trastuzumab deruxtecan to hear your experiences and inform our work. 

If you are able to help, please complete this short form https://breastcancernow.org/about-us/tell-us-your-story  by 12th August.

Any questions, please let me know. 

Thank you,

Holly